GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Piotroski F-Score

Hansoh Pharmaceutical Group Co (HKSE:03692) Piotroski F-Score : 5 (As of May. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hansoh Pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

HKSE:03692' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 5

During the past 8 years, the highest Piotroski F-Score of Hansoh Pharmaceutical Group Co was 6. The lowest was 3. And the median was 5.


Hansoh Pharmaceutical Group Co Piotroski F-Score Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Piotroski F-Score Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 5.00 3.00 5.00 6.00 5.00

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 - 6.00 - 5.00

Competitive Comparison of Hansoh Pharmaceutical Group Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was HK$3,585 Mil.
Cash Flow from Operations was HK$3,409 Mil.
Revenue was HK$11,051 Mil.
Gross Profit was HK$9,924 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (33503.54 + 36137.447) / 2 = HK$34820.4935 Mil.
Total Assets at the begining of this year (Dec22) was HK$33,504 Mil.
Long-Term Debt & Capital Lease Obligation was HK$114 Mil.
Total Current Assets was HK$31,592 Mil.
Total Current Liabilities was HK$7,506 Mil.
Net Income was HK$2,885 Mil.

Revenue was HK$10,477 Mil.
Gross Profit was HK$9,509 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (33256.743 + 33503.54) / 2 = HK$33380.1415 Mil.
Total Assets at the begining of last year (Dec21) was HK$33,257 Mil.
Long-Term Debt & Capital Lease Obligation was HK$4,871 Mil.
Total Current Assets was HK$28,847 Mil.
Total Current Liabilities was HK$2,925 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hansoh Pharmaceutical Group Co's current Net Income (TTM) was 3,585. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hansoh Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 3,409. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=3584.864/33503.54
=0.10699956

ROA (Last Year)=Net Income/Total Assets (Dec21)
=2885.308/33256.743
=0.08675859

Hansoh Pharmaceutical Group Co's return on assets of this year was 0.10699956. Hansoh Pharmaceutical Group Co's return on assets of last year was 0.08675859. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hansoh Pharmaceutical Group Co's current Net Income (TTM) was 3,585. Hansoh Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 3,409. ==> 3,409 <= 3,585 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=114.245/34820.4935
=0.00328097

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=4871.459/33380.1415
=0.14593884

Hansoh Pharmaceutical Group Co's gearing of this year was 0.00328097. Hansoh Pharmaceutical Group Co's gearing of last year was 0.14593884. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=31591.951/7506.439
=4.20864687

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=28846.55/2925.236
=9.86127273

Hansoh Pharmaceutical Group Co's current ratio of this year was 4.20864687. Hansoh Pharmaceutical Group Co's current ratio of last year was 9.86127273. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hansoh Pharmaceutical Group Co's number of shares in issue this year was 6019.65. Hansoh Pharmaceutical Group Co's number of shares in issue last year was 5929.483. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9923.793/11051.33
=0.89797273

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9509.273/10477.475
=0.90759205

Hansoh Pharmaceutical Group Co's gross margin of this year was 0.89797273. Hansoh Pharmaceutical Group Co's gross margin of last year was 0.90759205. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=11051.33/33503.54
=0.32985559

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=10477.475/33256.743
=0.31504814

Hansoh Pharmaceutical Group Co's asset turnover of this year was 0.32985559. Hansoh Pharmaceutical Group Co's asset turnover of last year was 0.31504814. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hansoh Pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Hansoh Pharmaceutical Group Co  (HKSE:03692) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hansoh Pharmaceutical Group Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines